Tecan Group AG /
Tecan CEO David Martyr forms new leadership team
. Processed and transmitted by Thomson Reuters ONE.
The issuer is solely responsible for the content of this announcement.
Männedorf, Switzerland, January 30, 2013 - The Tecan Group (SIX Swiss Exchange:
TECN) today announced that with the implementation of its growth strategy there
will also be some changes in the leadership team. Dr. David Martyr, who became
the new CEO of the Company in October 2012, is using the opportunity to
reorganize and strengthen the capabilities of the leadership team.
David Martyr said: "Tecan is a very strong brand in our industry and has an
excellent basis for future accelerated growth. With the expected start of the
commercial supply of instruments to our partners from two major OEM programs
within this year, we are preparing already for significant growth in the near
future. For the mid and long-term development of our business it is essential
that we have the right leadership team with extensive domain knowledge,
experience and capabilities. Through this renewal process of the management team
in various positions, I would like to take the opportunity to strengthen the
capabilities of the leadership team in a targeted manner."
In the context of this renewal process, Dr. Bernhard Grob, who has been Head of
the Partnering Business division and member of the Management Board since
January 2011, will be leaving the Company. The search for a successor is
underway.
Tecan's Board of Directors and CEO thank Bernhard Grob for his strong engagement
and the important service of developing Tecan's Partnering Business and wish him
all the best for the future.
The position of the Head of the Life Sciences division was already vacant at the
entry of David Martyr. The search for a successor is in a very advanced state
and an announcement of this position is expected in the near future.
With the increased importance of business and academic partnerships, licensing
as well as potential mergers and acquisitions it is also necessary for the
Corporate Development department to be strengthened. The search for a Head of
Corporate Development is underway.
About Tecan
Tecan (www.tecan.com) is a leading global provider of laboratory instruments and
solutions in biopharmaceuticals, forensics and clinical diagnostics. The company
specializes in the development, production and distribution of automated
workflow solutions for laboratories in the life sciences sector. Its clients
include pharmaceutical and biotechnology companies, university research
departments, and forensic and diagnostic laboratories. As an original equipment
manufacturer (OEM), Tecan is also a leader in developing and manufacturing OEM
instruments and components that are then distributed by partner companies.
Founded in Switzerland in 1980, the company has manufacturing, research and
development sites in both Europe and North America and maintains a sales and
service network in 52 countries. In 2011, Tecan generated sales of
CHFÂ 377Â million (USDÂ 424Â million; EURÂ 306Â million). Registered shares of Tecan
Group are traded on the SIX Swiss Exchange (TK: TECN/Reuters: TECZn.S/ ISIN:
1210019).
For further information:
Tecan Group
Martin Braendle
Head of Corporate Communications & Investor Relations
Tel. +41 (0) 44 922 84 30
Fax +41 (0) 44 922 88 89
investor@tecan.com
www.tecan.com
Press Release (PDF):
http://hugin.info/100384/R/1673974/545021.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Tecan Group AG via Thomson Reuters ONE
[HUG#1673974]